Welspun specialty solution has announced its quarterly earnings conference call to discuss Q3&9M FY26 financial results. The company formally notified BSE Limited on January 20, 2026, scheduling the investor interaction for January 27, 2026.

Conference Call Details

The earnings discussion is scheduled for Tuesday, January 27, 2026 at 4:00 PM Indian Standard Time. JM Financial Institutional Securities is hosting the conference call, providing a platform for investors and analysts to engage with the company's management team.

Management Participation

Key executives will represent the company during the earnings call, ensuring comprehensive coverage of financial performance and business developments.

Dial-in Information

The company has provided multiple access options for participants across different time zones. The universal dial-in numbers for domestic participants are +91-22-6280 1366 and +91-22-7115 8267.

International Toll-Free Numbers

Participants are advised to dial-in 10 minutes prior to the conference schedule to ensure proper connection. The call timing corresponds to 5:30 AM USA EDT, 10:30 AM UK time, and 6:30 PM Hong Kong/Singapore time.

Contact Information

JM Financial has designated specific contacts for further information regarding the conference call:

• Mr. Ashutosh Somani: +91-98332 91928, ashutosh.somani@jmfl.com
• Mr. Anirudh Nagpal: +91-81717 77974, anirudh.nagpal@jmfl.com
• Mr. Anuj Khandelwal: +91-92840 14227, anuj.khandelwal@jmfl.com

The formal notification was signed by Suhas Pawar, Company Secretary & Compliance Officer (ACS-36560), and submitted to BSE Limited under the company's scrip code 500365. This regulatory filing ensures compliance with disclosure requirements under Regulation 30.

Aurobindo Pharma Limited has announced an extension of its timeline for acquiring up to 26% stake in Swarnaakshu Solar Power Private Limited, pushing the completion date to March 31, 2026, from the previously announced December 31, 2025 deadline.

Investment Timeline Extension

The pharmaceutical company informed stock exchanges that the delay is attributed to pending receipt of state government approval for setting up a captive solar power plant. The company had previously communicated about this solar power initiative through multiple letters dated February 6, 2025, March 28, 2025, June 30, 2025, and September 26, 2025.

Regulatory Compliance

The update was shared under Regulation 30 of SEBI Listing Regulations, ensuring transparency with stakeholders regarding this development. Company Secretary B. Adi Reddy signed the disclosure, maintaining compliance with regulatory requirements for material information sharing.

Solar Power Strategy

The captive solar power purchase agreement represents Aurobindo Pharma's commitment to renewable energy adoption. The investment in Swarnaakshu Solar Power Private Limited aligns with the company's sustainability initiatives and long-term energy cost management strategy.

The completion of the required investment remains subject to receiving approval from the concerned state government, highlighting the regulatory dependencies involved in renewable energy project implementations.